Accueil   Diary - News   All news VALBIOTIS receives US and European TOTUM-070 patent for reducing hypercholesterolemia

VALBIOTIS receives US and European TOTUM-070 patent for reducing hypercholesterolemia

  • TOTUM-070 exclusivity guaranteed in the United States and in Europe for reducing blood LDL-cholesterol levels, a cardiovascular disease risk factor;

  • Intellectual property rights protecting the composition of the TOTUM-070 active substance for food and pharmaceutical applications;

  • A milestone in the further development of TOTUM-070, in the search for commercial partnerships and in receiving approval for health claims in Europe and North America.

 

La Rochelle, September 14, 2020 (5:40 pm CEST) VALBIOTIS (FR0013254851 - ALVAL, eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, has announced that it has obtained an American and European patent for TOTUM-070, its active substance dedicated to reducing LDL-cholesterol in the blood (“bad cholesterol”).

 

Read the press release